[Evaluation of the clinical efficacy of the effect of herbal medicine on the symptoms of SARS-COV-2 associated pharyngitis and the formation of post-covid syndrome]. / Otsenka klinicheskoi effektivnosti vliyaniya original'nogo rastitel'nogo lekarstvennogo preparata na simptomy SARS-CoV-2-assotsiirovannogo tonzillofaringita i formirovanie postkovidnogo sindroma.

Pharyngitis is one of the manifestations of SARS-CoV-2 infection, which features specific changes in the pharyngoscopic pattern, long fluctuating course and increase in symptoms severity after a physical exercise, which requires long-term therapy with topical agents. A comparative analysis of Tonsilgon N effect on the course of SARS-CoV-2 associated pharyngitis as well as post-COVID syndrome development was carried out in this study. 164 patients with acute pharyngitis associated with SARS-CoV-2 were included in the study. Main group (n=81) received Tonsilgon N oral drops in addition to the standard treatment regimens for pharyngitis and control group (n=83) received standard regimen alone. Treatment regimen lasted for 21 days for both groups, followed by follow up examination in 12 weeks for assessment of post-COVID syndrome development. Patients taking Tonsilgon N showed a statistically significant symptoms improvement in throat pain relief (p=0.002) and throat discomfort (p=0.004), however, no statistically significant difference in two groups were observed in inflammation severity based on pharyngoscopy examination (p=0.558). Addition of Tolzilgon N to the regimen reduced occurrence of secondary bacterial infections and therefore use of antibiotics more than 2.8 times (p<0.001). Compared with the control group long term topical therapy with Tolzilgon N showed no increase in occurrence of side effects such as allergic reactions (p=0.311) as well as subjective burning sensations in the throat (p=0.849). In main group occurrence of post-COVID syndrome was observed 3.3 times less than in the control group (7.2% vs 25.9%, p=0.001). These results give us the ground for indication of Tonsilgon N use in the treatment of viral pharyngitis associated with SARS-CoV 2 infection and in prevention of post-COVID syndrome.

[The optimization in the rehabilitation of anosmia after SARS-CoV-2 infection]. / Optimizatsiya sposobov vosstanovleniya obonyaniya pri anosmii, indutsirovannoi SARS-CoV-2-infektsiei.

During SARS-CoV-2 pandemic number of patients with olfactory disorders caused by new coronavirus infection substantially increased, making their rehabilitation an issue of the day. We analyzed influence of the drug Sinupret on the restoration dynamic of the olfactory dysfunction associated with SARS-CoV-2 infection. 187 patients with impaired sense of smell associated with SARS-CoV-2 infection were included in this study: test group consisted of 104 cases in which olfactory training methods were combined with the prescription of the drug Sinupret. Control group consisted of 84 patients those undergone olfactory training alone. During study period in 26 patients restoration of the olfactory disorders have not been achieved, due to the virus induced neurodegenerative nature of the lesion. It was observed that in test group odor detection threshold restoration was on average 3.6 days faster than in control group. At the same time, the use of Sinupret was associated with a statistically significant 29.4% decrease of antibiotic prescription frequency for bacterial complications of SARS-CoV-2. Therefore, we assume that the positive effect of Sinupret on SARS-CoV-2 associated anosmia is caused by its antiviral, secretolytic, anti-inflammatory, decongestant and moderately antibacterial effects in the olfactory epithelium.